PATENT CLAIM ANALYSIS

Application Number: 16128312
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "001000"]

Abstract:
Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Claim (Index 8):
The high-load solid tablet formulation of any one of  claims 1 - 7 , wherein at least one excipient is a diluent.

Metadata:
- Claim Count in Document: 89.0
- Percentile: 97.0
- Lexical Diversity: 1.51923
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15060010', '15909779', '15462444', '14821290', '15970721']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7597873819157775
- 35 USC 102 Novelty (BERT): 0.5981150434396425
- Combined Prediction Score: 0.743620148068164
- Mean Citation Score: 457.25797400000016
- Max Citation Score: 556.6536
- Similarity Product: 416.8064442810058

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test